Suanfarma, a prominent global leader in the development and production of active pharmaceutical ingredients (APIs) and high-value Contract Development and Manufacturing Organization (CDMO) services for the healthcare sector, has appointed Pere Mañé Godina as its new Chief Executive Officer (CEO). This transition marks a pivotal moment for the company, signaling its focus on strengthening its industrial presence, fostering sustainable innovation, and broadening its global reach.
With an extensive career spanning over three decades, Pere Mañé brings a wealth of expertise from top pharmaceutical companies such as Uquifa, Boehringer Ingelheim, and Esteve Química (Esteve Group). His journey has seen him take on various leadership roles, from technical and operational positions to executive titles like General Manager and Group Chief Industrial Operations Officer.
In his most recent role, Pere was instrumental in leading Esteve’s industrial transformation, which helped position the company’s chemical division as a global leader. Under his direction, Esteve was honored with the prestigious title of CDMO of the Year – Small Molecules at the DCAT 2025 Leadership Awards.
Carlos Alonso, who has served as the interim CEO of Suanfarma since October 2024, shared his confidence in the new appointment: “We are confident that Pere’s deep sector knowledge, strategic mindset, and leadership experience will be instrumental in strengthening Suanfarma’s market position and continuing to deliver high-value solutions to our customers and partners.”
Pere Mañé expressed his enthusiasm about the new role, stating: “Suanfarma has all the elements to lead the future of the industry: a solid foundation, a strong industrial platform, and a high-value international network supported by an exceptional team. I’m excited to begin this new chapter and work together to keep delivering innovative, efficient, and sustainable solutions to our clients.”
With this leadership change, Suanfarma is poised to continue its legacy of excellence while accelerating its commitment to innovation and global growth in the pharmaceutical and health industries.
Also read: Viksit Workforce for a Viksit Bharat
Do Follow: The Mainstream formerly known as CIO News LinkedIn Account | The Mainstream formerly known as CIO News Facebook | The Mainstream formerly known as CIO News Youtube | The Mainstream formerly known as CIO News Twitter |The Mainstream formerly known as CIO News Whatsapp Channel | The Mainstream formerly known as CIO News Instagram
About us:
The Mainstream formerly known as CIO News is a premier platform dedicated to delivering latest news, updates, and insights from the tech industry. With its strong foundation of intellectual property and thought leadership, the platform is well-positioned to stay ahead of the curve and lead conversations about how technology shapes our world. From its early days as CIO News to its rebranding as The Mainstream on November 28, 2024, it has been expanding its global reach, targeting key markets in the Middle East & Africa, ASEAN, the USA, and the UK. The Mainstream is a vision to put technology at the center of every conversation, inspiring professionals and organizations to embrace the future of tech.
